These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23994188)

  • 21. Structure-activity relationships in the development of allosteric hepatitis C virus RNA-dependent RNA polymerase inhibitors: ten years of research.
    Haudecoeur R; Peuchmaur M; Ahmed-Belkacem A; Pawlotsky JM; Boumendjel A
    Med Res Rev; 2013 Sep; 33(5):934-84. PubMed ID: 22893620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus.
    Horscroft N; Lai VC; Cheney W; Yao N; Wu JZ; Hong Z; Zhong W
    Antivir Chem Chemother; 2005; 16(1):1-12. PubMed ID: 15739617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel polymerase inhibitors shape new HCV combinations with telaprevir.
    AIDS Patient Care STDS; 2009 Apr; 23(4):309-10. PubMed ID: 19358693
    [No Abstract]   [Full Text] [Related]  

  • 24. Modification of hepatitis C virus 1b RNA polymerase to make a highly active JFH1-type polymerase by mutation of the thumb domain.
    Weng L; Du J; Zhou J; Ding J; Wakita T; Kohara M; Toyoda T
    Arch Virol; 2009; 154(5):765-73. PubMed ID: 19340394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of a novel resistance mutation for benzimidazole inhibitors of the HCV RNA-dependent RNA polymerase.
    Delang L; Froeyen M; Herdewijn P; Neyts J
    Antiviral Res; 2012 Jan; 93(1):30-8. PubMed ID: 22033247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and anti-HCV activity evaluation of anilinoquinoline derivatives.
    Peng HK; Lin CK; Yang SY; Tseng CK; Tzeng CC; Lee JC; Yang SC
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1107-10. PubMed ID: 22204909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imidazo[4,5-c]pyridines inhibit the in vitro replication of the classical swine fever virus and target the viral polymerase.
    Vrancken R; Paeshuyse J; Haegeman A; Puerstinger G; Froeyen M; Herdewijn P; Kerkhofs P; Neyts J; Koenen F
    Antiviral Res; 2008 Feb; 77(2):114-9. PubMed ID: 17997169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different mechanisms of hepatitis C virus RNA polymerase activation by cyclophilin A and B in vitro.
    Weng L; Tian X; Gao Y; Watashi K; Shimotohno K; Wakita T; Kohara M; Toyoda T
    Biochim Biophys Acta; 2012 Dec; 1820(12):1886-92. PubMed ID: 22954804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders.
    Eltahla AA; Tay E; Douglas MW; White PA
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7215-24. PubMed ID: 25246395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro.
    Lu L; Dekhtyar T; Masse S; Pithawalla R; Krishnan P; He W; Ng T; Koev G; Stewart K; Larson D; Bosse T; Wagner R; Pilot-Matias T; Mo H; Molla A
    Antiviral Res; 2007 Oct; 76(1):93-7. PubMed ID: 17561278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Studies on the anti-hepatitis C virus activity of newly synthesized tropolone derivatives: identification of NS3 helicase inhibitors that specifically inhibit subgenomic HCV replication.
    Najda-Bernatowicz A; Krawczyk M; Stankiewicz-Drogoń A; Bretner M; Boguszewska-Chachulska AM
    Bioorg Med Chem; 2010 Jul; 18(14):5129-36. PubMed ID: 20579888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resolution of the interaction mechanisms and characteristics of non-nucleoside inhibitors of hepatitis C virus polymerase.
    Winquist J; Abdurakhmanov E; Baraznenok V; Henderson I; Vrang L; Danielson UH
    Antiviral Res; 2013 Mar; 97(3):356-68. PubMed ID: 23305851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New non-nucleoside inhibitors of hepatitis C virus RNA-dependent RNA polymerase.
    Ivanov AV; Kozlov MV; Kuzyakin AO; Kostyuk DA; Tunitskaya VL; Kochetkov SN
    Biochemistry (Mosc); 2004 Jul; 69(7):782-8. PubMed ID: 15310279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The imidazopyrrolopyridine analogue AG110 is a novel, highly selective inhibitor of pestiviruses that targets the viral RNA-dependent RNA polymerase at a hot spot for inhibition of viral replication.
    Paeshuyse J; Chezal JM; Froeyen M; Leyssen P; Dutartre H; Vrancken R; Canard B; Letellier C; Li T; Mittendorfer H; Koenen F; Kerkhofs P; De Clercq E; Herdewijn P; Puerstinger G; Gueiffier A; Chavignon O; Teulade JC; Neyts J
    J Virol; 2007 Oct; 81(20):11046-53. PubMed ID: 17686854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of hepatitis C virus replication by Monascus pigment derivatives that interfere with viral RNA polymerase activity and the mevalonate biosynthesis pathway.
    Sun JM; Kim SJ; Kim GW; Rhee JK; Kim ND; Jung H; Jeun J; Lee SH; Han SH; Shin CS; Oh JW
    J Antimicrob Chemother; 2012 Jan; 67(1):49-58. PubMed ID: 22076990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compound.
    Madhvi A; Hingane S; Srivastav R; Joshi N; Subramani C; Muthumohan R; Khasa R; Varshney S; Kalia M; Vrati S; Surjit M; Ranjith-Kumar CT
    Sci Rep; 2017 Jul; 7(1):5816. PubMed ID: 28725041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Molecular virology of hepatitis C].
    Moradpour D; Brass V; Gosert R; Wölk B; Blum HE
    Praxis (Bern 1994); 2002 Dec; 91(51-52):2247-53. PubMed ID: 12564041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Purification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitors.
    Xu HT; Hassounah SA; Colby-Germinario SP; Oliveira M; Fogarty C; Quan Y; Han Y; Golubkov O; Ibanescu I; Brenner B; Stranix BR; Wainberg MA
    J Antimicrob Chemother; 2017 Mar; 72(3):727-734. PubMed ID: 28069884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection.
    Sheldon J; Barreiro P; Soriano V
    Expert Opin Investig Drugs; 2007 Aug; 16(8):1171-81. PubMed ID: 17685867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppression of hepatitis C virus replication by cyclin-dependent kinase inhibitors.
    Munakata T; Inada M; Tokunaga Y; Wakita T; Kohara M; Nomoto A
    Antiviral Res; 2014 Aug; 108():79-87. PubMed ID: 24893207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.